Halol plant remediation uncertainty
Halol plant remains under FDA scrutiny; no timeline for re-inspection or resolution, impacting US generic supply.
high · analyst_question
Sunpharma Ltd — Q2 FY24
Sun Pharma reported Q2 FY24 consolidated revenue of INR 12,003 crore, up 11% YoY, driven by India formulations (11.1% growth) and global specialty sales (19.3% growth to $240M).
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Taro Israel operations exposure
Taro's operations in Israel may be impacted by regional conflict, though management says business continuity is maintained.
medium · analyst_questionUS generic pricing pressure
Management sees no significant improvement in generic pricing environment; pricing remains product-specific and competitive.
medium · management_commentary